<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005588.pub2" GROUP_ID="NEONATAL" ID="648003051313295252" MERGED_FROM="" MODIFIED="2010-02-17 18:10:56 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;/p&gt;&lt;p&gt;CL 1/06 (protocol)&lt;/p&gt;&lt;p&gt;Sent to J. Ho Apr 17/06&lt;/p&gt;&lt;p&gt;CL 3/07 (review)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-02-17 12:04:28 -0500" NOTES_MODIFIED_BY="Diane Haughton" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2010-02-17 18:10:56 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Magnesium sulfate for persistent pulmonary hypertension of the newborn</TITLE>
<CONTACT MODIFIED="2010-02-17 18:10:56 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15233" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jacqueline</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Ho</LAST_NAME><POSITION>Head of Department</POSITION><EMAIL_1>jho@pc.jaring.my</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Penang Medical College</ORGANISATION><ADDRESS_1>4 Sepoy Lines</ADDRESS_1><CITY>Penang</CITY><ZIP>10450</ZIP><COUNTRY CODE="MY">Malaysia</COUNTRY><PHONE_1>+60 4 2263459</PHONE_1><PHONE_2>+60 5 2532863</PHONE_2><FAX_1>+60 4 2284285</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-02-17 18:10:56 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15233" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jacqueline</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Ho</LAST_NAME><POSITION>Head of Department</POSITION><EMAIL_1>jho@pc.jaring.my</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics</DEPARTMENT><ORGANISATION>Penang Medical College</ORGANISATION><ADDRESS_1>4 Sepoy Lines</ADDRESS_1><CITY>Penang</CITY><ZIP>10450</ZIP><COUNTRY CODE="MY">Malaysia</COUNTRY><PHONE_1>+60 4 2263459</PHONE_1><PHONE_2>+60 5 2532863</PHONE_2><FAX_1>+60 4 2284285</FAX_1></ADDRESS></PERSON><PERSON ID="25BFC3F482E26AA2004A583D66854B5B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ganesa</FIRST_NAME><LAST_NAME>Rasa</LAST_NAME><EMAIL_1>drgrasa@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Paediatrics</DEPARTMENT><ORGANISATION>Pantai Klang Specialist Medical Center</ORGANISATION><ADDRESS_1>Lot 5921, Persiaran Raja Muda Musa</ADDRESS_1><CITY>Klang</CITY><ZIP>41200</ZIP><REGION>Selangor</REGION><COUNTRY CODE="MY">Malaysia</COUNTRY><PHONE_1>603 3372 5222 ext. 357</PHONE_1><FAX_1>603 3371 5705</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-12-22 10:49:38 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 20/04/07&lt;/p&gt;" NOTES_MODIFIED="2009-12-22 10:49:38 -0500" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="22" MONTH="12" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="12" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="12" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2010-01-10 16:38:54 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-10 16:38:54 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="12" YEAR="2009"/>
<DESCRIPTION>
<P>This review updates the existing review "Magnesium sulfate for persistent pulmonary hypertension of the newborn" published in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Ho-2007" TYPE="REFERENCE">Ho 2007</LINK>).</P>
<P>Updated search found no new trials.</P>
<P>No changes to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-12-22 10:49:13 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-12-22 10:49:13 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="3" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Royal College of Medicine, Perak</NAME>
<COUNTRY CODE="MY">Malaysia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Dept of Paediatrics, Hospital Ipoh</NAME>
<COUNTRY CODE="MY">Malaysia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Kuala Lumpur</NAME>
<COUNTRY CODE="MY">Malaysia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-01-14 23:54:52 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-22 12:42:41 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-22 12:37:40 -0400" MODIFIED_BY="[Empty name]">Magnesium sulfate for persistent pulmonary hypertension of the newborn</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-22 12:42:41 -0400" MODIFIED_BY="[Empty name]">
<P>The blood pressure in the arteries of the lungs (pulmonary arteries) is normally much lower than the blood pressure in the rest of the body. Before a baby is born the muscle surrounding the pulmonary arteries is tightly constricted resulting in a very high pressure in these arteries. After birth the arteries dilate and the pressure drops. In persistent pulmonary hypertension of the newborn this drop in pulmonary blood pressure, for a variety of reasons, fails to occur.</P>
<P>Magnesium sulfate is able to dilate constricted muscles of the type in the pulmonary arteries. However, its action is not specific and when given via an intravenous infusion, it will act on other muscles in the body including other arteries. This means that even if it were found to be effective in pulmonary hypertension, unwanted actions in other parts of the body might be a problem.</P>
<P>This review found that the use of magnesium sulfate for persistent pulmonary hypertension of the newborn has not been tested by randomized controlled trials. Evidence from uncontrolled studies is extremely limited but since the little evidence that does exist suggests a potential benefit, randomized controlled trials are recommended. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-01-10 16:39:24 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-01-05 20:49:19 -0500" MODIFIED_BY="[Empty name]">
<P>Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO) in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies. Magnesium sulfate is a potent vasodilator and hence has the potential to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the treatment of PPHN, this could be a cost effective and potentially life-saving therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the use of magnesium sulfate compared with placebo or standard ventilator management alone, sildenafil infusion, adenosine infusion, or inhaled nitric oxide on mortality or the use of backup iNO or ECMO in term and near-term newborns (&gt; 34 weeks gestational age) with PPHN.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-01-10 16:39:24 -0500" MODIFIED_BY="[Empty name]">
<P>The standard search strategy of the Cochrane Neonatal Review Group (CNRG) was used. No language restrictions was applied. The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2006) and MEDLINE (1966 to April 20, 2007) were searched for relevant randomized and quasi-randomized trials. In addition the reference lists of retrieved articles were reviewed and known experts were contacted to obtain unpublished data. This search was updated in December 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised or quasi-random studies were eligible where one of the treatment groups received magnesium sulfate for PPHN. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Standard methods of the Cochrane Collaboration and the CNRG were used, including independent assessment of trial quality and extraction of data by each author.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No eligible trials were found</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>On the basis of the current lack of evidence, the use of magnesium sulphate cannot be recommended in the treatment of PPHN. Randomised controlled trials are recommended.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-01-14 23:54:52 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-01-14 23:54:52 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-01-10 16:39:35 -0500" MODIFIED_BY="[Empty name]">
<P>The incidence of persistent pulmonary hypertension of the newborn (PPHN) varies widely depending on the center. Walsh-Sukys estimated the incidence of PPHN to be 1.9/1000 live births (0.43 to 6.82 per 1,000 live births)(<LINK REF="REF-Walsh_x002d_Sukys-2000" TYPE="REFERENCE">Walsh-Sukys 2000</LINK>). PPHN can occur as a primary condition or be secondary to meconium aspiration, respiratory distress syndrome, infection or congenital diaphragmatic hernia (<LINK REF="REF-Finer-2004" TYPE="REFERENCE">Finer 2004</LINK>). Approximately half of infants with PPHN have meconium aspiration syndrome.</P>
<P>There are no data on the incidence of PPHN in developing countries, but since birth asphyxia and meconium aspiration occur more frequently in this setting (<LINK REF="REF-Ellis-2000" TYPE="REFERENCE">Ellis 2000</LINK>; <LINK REF="REF-Nasheit-2003" TYPE="REFERENCE">Nasheit 2003</LINK>; <LINK REF="REF-Moodley-1998" TYPE="REFERENCE">Moodley 1998</LINK>; <LINK REF="REF-Costello-1994" TYPE="REFERENCE">Costello 1994</LINK>), it is likely PPHN also occurs more frequently.</P>
<P>There is no universally agreed upon definition for PPHN. The diagnosis is usually based on clinical features; the patient is hypoxic in spite of maximal ventilation and oxygen supplementation (<LINK REF="STD-Tolsa-1995" TYPE="STUDY">Tolsa 1995</LINK>). Echocardiography is used to confirm the diagnosis by demonstrating right to left shunting at the ductal or atrial level with posterior systolic bowing of the interventricular septum or systolic pulmonary artery pressure (PAP) greater than or equal to 75% of systolic aortic pressure (<LINK REF="REF-Davidson-1998" TYPE="REFERENCE">Davidson 1998</LINK>). PAP is estimated by measuring the tricuspid regurgitant jet gradient (<LINK REF="REF-Skinner-1993" TYPE="REFERENCE">Skinner 1993</LINK>); however, facilities for these measurements may not always be available. An alternative method for establishing the diagnosis is the measurement of a preductal versus postductal transcutaneous oxygen saturation gradient of 10% or greater (<LINK REF="REF-Davidson-1998" TYPE="REFERENCE">Davidson 1998</LINK>). However, the outcome is similar whether the diagnosis is based on clinical criteria or on the presence of echocardiographic evidence of PPHN (<LINK REF="REF-Finer-2004" TYPE="REFERENCE">Finer 2004</LINK>).</P>
<P>Generally, newborns with PPHN are paralyzed or sedated and placed on intermittent positive pressure ventilation (IPPV). High frequency oscillatory ventilation has been used, but there is little data from randomized controlled trials to support its efficacy (<LINK REF="REF-Bhuta-2005" TYPE="REFERENCE">Bhuta 2005</LINK>). Inhaled nitric oxide (iNO) is the only known selective pulmonary vasodilator, by virtue of being directly delivered to the airways. Inhaled nitric oxide improves oxygenation in 50% of treated infants and reduces the requirement for ECMO (<LINK REF="REF-Finer-2004" TYPE="REFERENCE">Finer 2004</LINK>). ECMO is considered the last line of management. Besides iNO and ECMO, other treatments described include intravenous or nebulized tolazoline (<LINK REF="REF-Parida-1997" TYPE="REFERENCE">Parida 1997</LINK>; <LINK REF="REF-Welch-1995" TYPE="REFERENCE">Welch 1995</LINK>), intravenous adenosine (<LINK REF="STD-Konduri-1996" TYPE="STUDY">Konduri 1996</LINK>; <LINK REF="REF-Ng-2004" TYPE="REFERENCE">Ng 2004</LINK>) and intravenous sildenafil (<LINK REF="REF-Shekerdemian-2002" TYPE="REFERENCE">Shekerdemian 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-01-05 20:53:52 -0500" MODIFIED_BY="[Empty name]">
<P>The drawback with many of the conventional therapies (iNO, ECMO) is the expense and required technical expertise. Many neonatal units in developing countries do not have the resources for these interventions. If magnesium sulfate were shown to be effective in the treatment of PPHN, then perhaps some lives could be saved in the developing world.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-01-05 20:53:14 -0500" MODIFIED_BY="[Empty name]">
<P>The use of magnesium sulfate for the treatment of PPHN has been described. Non-randomized studies using magnesium sulfate in doses of 20 - 100 mg/kg/hour (preceded by a loading dose of 200 mg/kg) suggest it may be effective (<LINK REF="STD-Abu_x002d_Osba-1992" TYPE="STUDY">Abu-Osba 1992</LINK>; <LINK REF="STD-Tolsa-1995" TYPE="STUDY">Tolsa 1995</LINK>; <LINK REF="STD-Daffa-2002" TYPE="STUDY">Daffa 2002</LINK>). It is a potent vasodilator. The exact mechanism of action of magnesium sulfate in PPHN is only partially understood. Animal studies have established that magnesium sulfate is a modulator of vascular contraction. It activates many cellular processes, including cation transport, and modulates membrane excitability. It is also a physiological calcium antagonist. Magnesium decreases the frequency of depolarization of smooth muscle by modulating calcium uptake, binding and distribution in smooth muscle cells, thereby promoting vasodilatation (<LINK REF="REF-Turlapaty-1978" TYPE="REFERENCE">Turlapaty 1978</LINK>). Magnesium sulfate may help in PPHN due to its sedative, muscle relaxant and bronchodilator effects, or by its associated alkalosis (<LINK REF="REF-Patole-1995" TYPE="REFERENCE">Patole 1995</LINK>). It has been used in a variety of other conditions including myocardial infarction, severe bronchial asthma, migraine and mania. (<LINK REF="REF-MAGIC-2002" TYPE="REFERENCE">MAGIC 2002</LINK>; <LINK REF="REF-Rowe-2005" TYPE="REFERENCE">Rowe 2005</LINK>; <LINK REF="REF-Bigal-2002" TYPE="REFERENCE">Bigal 2002</LINK>; <LINK REF="REF-Heiden-1999" TYPE="REFERENCE">Heiden 1999</LINK>). Excessive magnesium causes hypotonia, hypotension, and cardiorespiratory failure (<LINK REF="REF-Andrews-1965" TYPE="REFERENCE">Andrews 1965</LINK>; <LINK REF="REF-Brady-1967" TYPE="REFERENCE">Brady 1967</LINK>; <LINK REF="REF-Lipitz-1971" TYPE="REFERENCE">Lipitz 1971</LINK>; <LINK REF="REF-Mofenson-1991" TYPE="REFERENCE">Mofenson 1991</LINK>; <LINK REF="REF-Sullivan-2000" TYPE="REFERENCE">Sullivan 2000</LINK>; <LINK REF="REF-Ali-2003" TYPE="REFERENCE">Ali 2003</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-01-14 23:54:52 -0500" MODIFIED_BY="[Empty name]">
<P>Magnesium sulfate has been extensively used in the management of preeclampsia. A systematic review of magnesium sulfate as a tocolytic agent found an association between use of magnesium sulfate and increased mortality in the infant, raising concern for its use (<LINK REF="REF-Crowther-2003a" TYPE="REFERENCE">Crowther 2003a</LINK>). However, other research has suggested that magnesium sulfate is neuroprotective (<LINK REF="REF-Crowther-2003" TYPE="REFERENCE">Crowther 2003</LINK>). A Cochrane review has shown that magnesium sulfate is neuroprotective to the fetus (<LINK REF="REF-Doyle-2009" TYPE="REFERENCE">Doyle 2009</LINK>). A further Cochrane protocol is evaluating its potential neuroprotective effect on the neonate following perinatal asphyxia (<LINK REF="REF-Kent-2003" TYPE="REFERENCE">Kent 2003</LINK>).</P>
<P>This systematic review compares magnesium sulfate with either with placebo or no treatment or with other active treatment in infants with PPHN.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-01-10 16:40:28 -0500" MODIFIED_BY="[Empty name]">
<P>To determine the effect of magnesium sulfate on mortality, the use of backup iNO or ECMO, and neurodevelopmental outcome in term and near-term newborns (&gt; 34 weeks gestational age) with PPHN.<BR/>Treatment with magnesium sulfate will be compared to:<BR/>
</P>
<UL>
<LI>placebo or standard ventilator management alone;</LI>
<LI>sildenafil infusion;</LI>
<LI>adenosine infusion;</LI>
<LI>inhaled nitric oxide.</LI>
</UL>
<P>Subgroup analysis was planned on the basis of diagnosis of PPHN:<BR/>
</P>
<UL>
<LI>echocardiographic diagnosis vs. criteria defining severity of the hypoxia or pre and postductal gradient;</LI>
<LI>ventilator support vs. no ventilator support.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2010-01-10 16:55:38 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-01-10 16:41:21 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized or quasi-randomized studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Term and near term neonates (&gt; 34 weeks gestation at birth and &lt; 1 month of age) with PPHN diagnosed by degree of hypoxia [such as PaO2 of less than 50 mm Hg or 6.67 kPa or Oxygenation Index (OI) &gt; 25] or echocardiographic criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-01-10 16:41:02 -0500" MODIFIED_BY="[Empty name]">
<P>Magnesium sulfate infusion of any dose or duration.</P>
<P>The comparison group would be:<BR/>
</P>
<UL>
<LI>placebo or standard ventilator management alone;</LI>
<LI>sildenafil infusion;</LI>
<LI>adenosine infusion;</LI>
<LI>inhaled nitric oxide.</LI>
</UL>
<P>Both groups may or may not be on assisted ventilation.<BR/>Treatment backup with iNO and ECMO was allowed in either group.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-01-10 16:41:21 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-01-10 16:41:11 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>All cause mortality to hospital discharge or 28 days of age.</LI>
<LI>Use of inhaled nitric oxide or ECMO.</LI>
<LI>Mortality or the use of backup therapy (iNO or ECMO).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-01-10 16:41:21 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Failure to improve oxygenation within 30 to 60 minutes (dichotomous variable).</LI>
<LI>Short term effect on oxygenation index and arterial PO2 after therapy (both absolute values and change from baseline).</LI>
<LI>Neurodisability (&gt; 2 standard deviation below the mean on a validated assessment tool) in first year of life.</LI>
<LI>Neurodisability (&gt; 2 standard deviation below the mean on a validated assessment tool) in childhood and beyond.</LI>
<LI>Cerebral palsy on physician assessment.</LI>
<LI>Hearing impairment.</LI>
<LI>Duration of hospital stay (days).</LI>
<LI>Adverse effects such as hypocalcaemia and hypokalemia, cardiac arrhythmias and severe hypotension.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-01-05 20:57:10 -0500" MODIFIED_BY="[Empty name]">
<P>The standard search strategy of the Cochrane Neonatal Review Group (CNRG) was used. </P>
<ELECTRONIC_SEARCHES MODIFIED="2010-01-05 20:57:10 -0500" MODIFIED_BY="[Empty name]">
<P>We searched the latest issue of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2006) and MEDLINE from 1966 up to April 20, 2007 for all reports of relevant randomized and quasi-randomized trials. The search strategy for CENTRAL and MEDLINE used the MeSH terms infant newborn, AND magnesium sulfate, AND (persistent fetal circulation OR the keywords pulmonary hypertension OR persistent pulmonary hypertension of the newborn). No language restrictions were applied.</P>
<P>In December 2009, we updated the search as follows: MEDLINE (search via PubMed), CINAHL, EMBASE and CENTRAL (<I>The Cochrane Library</I>) were searched from 1999 to 2009. Search terms: magnesium sulfate AND persistent fetal circulation OR pulmonary hypertension OR persistent pulmonary hypertension of the newborn. Limits: human, infant and clinical trial. No language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-01-05 20:56:44 -0500" MODIFIED_BY="[Empty name]">
<P>In addition to the electronic search, we reviewed the reference lists of retrieved articles and to obtain unpublished data contacted known experts.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-01-10 16:55:38 -0500" MODIFIED_BY="[Empty name]">
<P>The standard methods of the CNRG were used.</P>
<STUDY_SELECTION MODIFIED="2010-01-10 16:55:38 -0500" MODIFIED_BY="[Empty name]">
<P>All randomized and quasi-randomized controlled trials fulfilling the selection criteria described in the previous section were to be included. Two investigators reviewed the results of the search separately for selection of the studies for inclusion. The review authors resolved any disagreement by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-01-06 08:00:22 -0500" MODIFIED_BY="[Empty name]">
<P>If studies were deemed eligible for inclusion, two review authors planned to separately extract, assess and code all data for each study using a form that was designed specifically for this review.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-01-10 16:53:34 -0500" MODIFIED_BY="[Empty name]">
<P>Independent assessment of retrieved reports for methodological quality and eligibility by each review author was planned. If trials were found evaluation of the quality of these trials would include blinding of randomization, completion of follow up and blinding of outcome assessment.If available, this information would be entered into the "Characteristics of Included Studies" table.</P>
<P>If studies were located for the 2009 update, we planned to complete the Risk of Bias table. If studies were deemed appropriate for inclusion, two authors planned to independently assess the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.  </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-01-06 08:03:44 -0500" MODIFIED_BY="[Empty name]">
<P>Statistical analyses were to be performed using Review Manager software. If available, categorical data were to be analyzed using relative risk (RR), risk difference (RD) and the number needed to treat (NNT). Continuous data were to be analyzed using weighted mean difference (WMD). The 95% Confidence interval (CI) was to be reported on all estimates as a measure of uncertainty.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-01-10 16:54:05 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to estimate the treatment effects of individual trials and examine heterogeneity between trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I<SUP>2 </SUP>statistic. If we detected statistical heterogeneity, we planned to explore the possible causes (for example, differences in study quality, participants, intervention regimens, or outcome assessments) using <I>post hoc</I> subgroup analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-01-05 21:05:23 -0500" MODIFIED_BY="[Empty name]">
<P>If multiple studies were identified and meta-analysis was judged to be appropriate, the analysis would have been performed using Review Manager software (RevMan 5), supplied by the Cochrane Collaboration. For estimates of typical relative risk and risk difference, we planned to use the Mantel-Haenszel method. For measured quantities, we planned to use the inverse variance method. All meta-analyses were to be done using the fixed effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-01-05 20:58:34 -0500" MODIFIED_BY="[Empty name]">
<P>A sensitivity analysis was planned based on trial quality.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-10 16:57:17 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-01-10 16:57:17 -0500" MODIFIED_BY="[Empty name]">
<P>Five clinical trials of magnesium sulfate were identified (<LINK REF="STD-Abu_x002d_Osba-1992" TYPE="STUDY">Abu-Osba 1992</LINK>; <LINK REF="STD-Chandran-2004" TYPE="STUDY">Chandran 2004</LINK>; <LINK REF="STD-Daffa-2002" TYPE="STUDY">Daffa 2002</LINK>; <LINK REF="STD-Tolsa-1995" TYPE="STUDY">Tolsa 1995</LINK>; <LINK REF="STD-Wu-1995" TYPE="STUDY">Wu 1995</LINK>). All were uncontrolled trials. In addition, one randomised controlled trial using adenosine (<LINK REF="STD-Konduri-1996" TYPE="STUDY">Konduri 1996</LINK>) and one using sildenafil (<LINK REF="STD-Baquero-2006" TYPE="STUDY">Baquero 2006</LINK>) for PPHN was found. Neither study compared the intervention to magnesium sulfate. The reasons for exclusion are given in the table of excluded studies. No studies that met the inclusion criteria of the review were found.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No randomized controlled trials were found for inclusion in the review.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>No randomized controlled trials were found for inclusion in the review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-01-10 16:42:59 -0500" MODIFIED_BY="[Empty name]">
<P>There is extremely limited information on the use of magnesium sulfate for PPHN. Of the five uncontrolled clinical studies identified, four were on term infants (<LINK REF="STD-Abu_x002d_Osba-1992" TYPE="STUDY">Abu-Osba 1992</LINK>; <LINK REF="STD-Chandran-2004" TYPE="STUDY">Chandran 2004</LINK>; <LINK REF="STD-Daffa-2002" TYPE="STUDY">Daffa 2002</LINK>; <LINK REF="STD-Wu-1995" TYPE="STUDY">Wu 1995</LINK>) and included a total of only 40 patients. One further study included seven preterm infants (<LINK REF="STD-Wu-1995" TYPE="STUDY">Wu 1995</LINK>). In all studies, the diagnosis was made on clinical grounds. In one study, the investigators did echocardiogram on all infants prior to starting magnesium sulfate. All patients were on mechanical ventilation prior to magnesium sulfate infusion. In all studies, a loading dose of 200 mg/kg was used and was followed by a continuous infusion of 20 to 150 mg/kg/hr. Magnesium levels were measured and the dose was adjusted to maintain a normal blood level. All studies showed a significant improvement in oxygenation measured by changes in partial oxygen pressure, alveolar-arterial oxygen index, oxygen index or change in ventilatory requirement. In three of the studies inotropes were given to all or most patients. Only one study did not use inotropic agents. In this study, there was a transient fall in blood pressure two hours after commencing the infusion that normalized by eight hours. One study reported a transient bradycardia that was corrected by dobutamine infusion. No other adverse effects were reported. Of the 40 infants, 35 survived. Two were reported to have bronchopulmonary dysplasia, one of whom died. Most studies reported the one year outcome. None had formal neurological assessment, but all reported that all survivors were developing normally. One study did formal hearing assessment and reported no hearing loss.</P>
<P>Given the consistent improvement noted in these four observational studies involving term infants, randomized controlled trials should be performed. As high income countries have access to the expensive but effective treatment iNO, such studies would have to be done in this setting. PPHN is not a common condition and developing countries may consider it a low priority, preferring to channel scarce manpower and resources into areas likely to result in greater reductions in mortality. The low incidence of this condition would also mean that any studies would have to be multicenter, posing further difficulties for resource poor countries wishing to tackle this question.</P>
<P>Although these studies suggested an improvement in oxygenation following infusion of magnesium sulphate, there is no evidence from randomized controlled trials to support its use. Given the absence of evidence, magnesium sulfate cannot be recommended as a treatment for PPHN.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no evidence of benefit or harm in the use of magnesium sulfate for PPHN.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Uncontrolled clinical trials suggest a potential benefit of magnesium sulfate in infants with PPHN. Since magnesium sulfate is inexpensive and potentially beneficial, randomized controlled trials are recommended. Such trials could be carried out in settings where iNO or ECMO are not available. Besides mortality, outcome measures should include adverse effects such as the incidence of hypotension, hypocalcaemia, apnea and cardiac arrhythmias. Survivors should be followed up for neurodevelopmental outcome.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-01-11 09:11:11 -0500" MODIFIED_BY="[Empty name]">
<P>The Cochrane Neonatal Review Group has been funded in part with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-10 16:58:10 -0500" MODIFIED_BY="[Empty name]">
<P>GR wrote the protocol with input from JJH<BR/>JJH performed the search and wrote the review with input from GR</P>
<P>The recent update (December 2009) was conducted centrally by the Cochrane Neonatal Review Group staff (Yolanda Montagne, Diane Haughton and Roger Soll) and reviewed and approved by JJH.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-01-25 14:10:56 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-01-10 16:59:11 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2010-01-10 16:59:11 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abu_x002d_Osba-1992" NAME="Abu-Osba 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Osba YK, Galal O, Manasra K, Rejjal A</AU>
<TI>Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baquero-2006" MODIFIED="2010-01-10 16:58:56 -0500" MODIFIED_BY="[Empty name]" NAME="Baquero 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-10 16:58:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baquero H, Soliz A, Neira F, Venegas ME, Sola A</AU>
<TI>Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>117</VL>
<PG>1077-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chandran-2004" NAME="Chandran 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chandran S, Haque ME, Wickramasinghe HR, Wint Z</AU>
<TI>Use of magnesium sulphate in severe persistent pulmonary hypertension of the newborn</TI>
<SO>Journal of Tropical Pediatrics</SO>
<YR>2004</YR>
<VL>50</VL>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daffa-2002" MODIFIED="2010-01-10 16:59:11 -0500" MODIFIED_BY="[Empty name]" NAME="Daffa 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-10 16:59:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daffa SH, Milaat WA</AU>
<TI>Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the newborn</TI>
<SO>Saudi Medical Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>1266-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konduri-1996" NAME="Konduri 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konduri GG, Garcia DC, Kazzi NJ, Shankaran S</AU>
<TI>Adenosine infusion improves oxygenation in term infants with respiratory failure</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>97</VL>
<PG>295-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tolsa-1995" NAME="Tolsa 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A</AU>
<TI>Magnesium sulphate as an alternative and sage treatment for severe persistent pulmonary hypertension of the newborn</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1995</YR>
<VL>72</VL>
<PG>F184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1995" NAME="Wu 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu TJ, Teng RJ, Tsou KI</AU>
<TI>Persistent pulmonary hypertension of the newborn treated with magnesium sulfate in premature neonates</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<PG>472-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Boo-2004" NAME="Boo 2004" YEAR="2004">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-01-25 14:10:56 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-01-25 14:10:56 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ali-2003" NAME="Ali 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ali A, Walentik C, Mantych GJ, Sadiq F, Keenan WJ, Noguchi A</AU>
<TI>Iatrogenic acute hypermagnesemia after total parenteral nutrition infusion mimicking septic shock syndrome: two case reports</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>e70-2. URL: http://www.pediatrics.org/cgi/content/full/112/1/e70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andrews-1965" NAME="Andrews 1965" TYPE="JOURNAL_ARTICLE">
<AU>Andrews BF, Campbell DR, Thomas P</AU>
<TI>Effects of hypertonic magnesium-sulphate enemas on newborn and young lambs</TI>
<SO>Lancet</SO>
<YR>1965</YR>
<VL>ii</VL>
<PG>64-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhuta-2005" MODIFIED="2008-08-22 11:51:35 -0400" MODIFIED_BY="[Empty name]" NAME="Bhuta 2005" TYPE="COCHRANE_REVIEW">
<AU>Bhuta T, Clark RH, Henderson-Smart DJ</AU>
<TI>Rescue high frequency oscillatory ventilation vs conventional ventilation for infants with severe pulmonary dysfunction born at or near term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-22 11:51:35 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 11:51:35 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002974"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bigal-2002" NAME="Bigal 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bigal ME, Bordini CA, Tepper SJ, Speciali JG</AU>
<TI>Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study</TI>
<SO>Cephalalgia</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brady-1967" NAME="Brady 1967" TYPE="JOURNAL_ARTICLE">
<AU>Brady JP, Williams HC</AU>
<TI>Magnesium intoxication in a premature infant</TI>
<SO>Pediatrics</SO>
<YR>1967</YR>
<VL>40</VL>
<PG>100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costello-1994" NAME="Costello 1994" TYPE="JOURNAL_ARTICLE">
<AU>Costello AM, Manandhar DS</AU>
<TI>Perinatal asphyxia in less developed countries</TI>
<SO>Archives of Disease in Childhood Fetal and Neonatal Edition</SO>
<YR>1994</YR>
<VL>71</VL>
<PG>F1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2003" MODIFIED="2010-01-14 23:46:37 -0500" MODIFIED_BY="[Empty name]" NAME="Crowther 2003" TYPE="JOURNAL_ARTICLE">
<AU>Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group</AU>
<TI>Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<PG>2669-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 14645308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crowther-2003a" MODIFIED="2008-08-22 11:48:02 -0400" MODIFIED_BY="[Empty name]" NAME="Crowther 2003a" TYPE="COCHRANE_REVIEW">
<AU>Crowther CA, Hiller JE, Doyle LW</AU>
<TI>Magnesium sulphate for preventing preterm birth in threatened preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-22 11:48:02 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 11:48:02 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1998" NAME="Davidson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al</AU>
<TI>Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>325-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 9480993"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2009" MODIFIED="2010-01-25 14:10:56 -0500" MODIFIED_BY="[Empty name]" NAME="Doyle 2009" TYPE="COCHRANE_REVIEW">
<AU>Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D</AU>
<TI>Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-01-25 14:10:44 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 14:10:44 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="CD004661. DOI: 10.1002/14651858.CD004661.pub3."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2000" NAME="Ellis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ellis M, Manandhar DS, Manandhar N, Wyatt J, Bolam AJ, Costello AM</AU>
<TI>Stillbirths and neonatal encephalopathy in Kathmandu, Nepal: an estimate of the contribution of birth asphyxia to perinatal mortality in a low-income urban population</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>39-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finer-2004" MODIFIED="2008-08-22 11:53:39 -0400" MODIFIED_BY="[Empty name]" NAME="Finer 2004" TYPE="COCHRANE_REVIEW">
<AU>Finer NN, Barrington KJ</AU>
<TI>Nitric oxide for respiratory failure in infants born at or near term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-22 11:53:39 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 11:53:39 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000399.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heiden-1999" NAME="Heiden 1999" TYPE="JOURNAL_ARTICLE">
<AU>Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S</AU>
<TI>Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy</TI>
<SO>Psychiatry Research</SO>
<YR>1999</YR>
<VL>89</VL>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kent-2003" MODIFIED="2008-08-22 11:48:50 -0400" MODIFIED_BY="[Empty name]" NAME="Kent 2003" TYPE="COCHRANE_REVIEW">
<AU>Kent A, Kecskes Z</AU>
<TI>Magnesium sulfate for term infants following perinatal asphyxia. [Protocol]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-22 11:48:50 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 11:48:50 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004494"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lipitz-1971" NAME="Lipitz 1971" TYPE="JOURNAL_ARTICLE">
<AU>Lipitz JP</AU>
<TI>The clinical and biochemical effects of excess magnesium in the newborn</TI>
<SO>Pediatrics</SO>
<YR>1971</YR>
<VL>47</VL>
<PG>501-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MAGIC-2002" NAME="MAGIC 2002" TYPE="JOURNAL_ARTICLE">
<AU>Magnesium in Coronaries (MAGIC) Trial Investigators</AU>
<TI>Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>1189-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mofenson-1991" NAME="Mofenson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Mofenson HC, Caraccio TR</AU>
<TI>Magnesium intoxication in a neonate from oral magnesium hydroxide laxative</TI>
<SO>Clinical Toxicology</SO>
<YR>1991</YR>
<VL>29</VL>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moodley-1998" NAME="Moodley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moodley J, Matchaba P, Payne AJ</AU>
<TI>Intrapartum amnioinfusion for meconium-stained liquor in developing countries</TI>
<SO>Tropical Doctor</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>31-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nasheit-2003" NAME="Nasheit 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nasheit NA</AU>
<TI>Perinatal and neonatal mortality and morbidity in Iraq</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<PG>64-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ng-2004" NAME="Ng 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ng C, Franklin O, Vaidya M, Pierce C, Petros A</AU>
<TI>Adenosine infusion for the management of persistent pulmonary hypertension of the newborn</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parida-1997" NAME="Parida 1997" TYPE="JOURNAL_ARTICLE">
<AU>Parida SK, Baker S, Kuhn R, Desai N, Pauly TH</AU>
<TI>Endotracheal tolazoline administration in neonates with persistent pulmonary hypertension</TI>
<SO>Journal of Perinatology</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>461&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patole-1995" NAME="Patole 1995" TYPE="JOURNAL_ARTICLE">
<AU>Patole SK, Finer NN</AU>
<TI>Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension</TI>
<SO>Magnesium Research</SO>
<YR>1995</YR>
<VL>8</VL>
<PG>373-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 8861137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rowe-2005" MODIFIED="2008-08-22 11:52:31 -0400" MODIFIED_BY="[Empty name]" NAME="Rowe 2005" TYPE="COCHRANE_REVIEW">
<AU>Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr</AU>
<TI>Magnesium sulfate for treating exacerbations of acute asthma in the emergency department</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-08-22 11:52:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 11:52:31 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001490"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shekerdemian-2002" NAME="Shekerdemian 2002" TYPE="JOURNAL_ARTICLE">
<AU>Shekerdemian LS, Ravn HB, Penny DJ</AU>
<TI>Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<PG>1098-102</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21952258"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Skinner-1993" NAME="Skinner 1993" TYPE="JOURNAL_ARTICLE">
<AU>Skinner JR, Stuart AG, O'Sullivan J, Heads A, Boys RJ, Hunter S</AU>
<TI>Right heart pressure determination by Doppler in infants with tricuspid regurgitation</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>216-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-2000" NAME="Sullivan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan JE, Berman BW</AU>
<TI>The pediatric forum; hypermagnesemia with lethargy and hypotonia due to administration of magnesium hydroxide to a 4-week old infant</TI>
<SO>Archives of Pediatric and Adolescent Medicine</SO>
<YR>2000</YR>
<VL>154</VL>
<PG>1272-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turlapaty-1978" NAME="Turlapaty 1978" TYPE="JOURNAL_ARTICLE">
<AU>Turlapaty PD, Altura BM</AU>
<TI>Extracellular magnesium ions control calcium exchange and content of vascular smooth muscle</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1978</YR>
<VL>52</VL>
<PG>421-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh_x002d_Sukys-2000" NAME="Walsh-Sukys 2000" TYPE="JOURNAL_ARTICLE">
<AU>Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK et al</AU>
<TI>Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<PG>14-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="UI: 10617698"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Welch-1995" NAME="Welch 1995" TYPE="JOURNAL_ARTICLE">
<AU>Welch JC, Bridson JM, Gibbs B</AU>
<TI>Endotracheal tolazoline for severe persistent pulmonary hypertension of the newborn</TI>
<SO>British Heart Journal</SO>
<YR>1995</YR>
<VL>73</VL>
<PG>99&#8211;100</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-01-10 16:49:00 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ho-2007" MODIFIED="2010-01-10 16:49:00 -0500" MODIFIED_BY="[Empty name]" NAME="Ho 2007" TYPE="COCHRANE_REVIEW">
<AU>Ho JJ, Rasa G</AU>
<TI>Magnesium sulfate for persistent pulmonary hypertension of the newborn</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-01-10 16:49:00 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-10 16:49:00 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005588.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-22 12:44:39 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abu_x002d_Osba-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baquero-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Sildenafil was not compared with magnesium sulfate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chandran-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daffa-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Konduri-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of adenosine compared with normal saline. No comparison with magnesium sulfate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tolsa-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study on preterm infants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-10-22 12:44:39 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-10-22 12:44:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boo-2004">
<CHAR_STUDY_NAME MODIFIED="2008-10-22 12:44:34 -0400" MODIFIED_BY="[Empty name]"/>
<CHAR_METHODS MODIFIED="2008-10-22 12:44:37 -0400" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2008-10-22 12:44:39 -0400" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2008-10-22 12:44:30 -0400" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>